• LinkedIn
  • Mail
About Medifactia ABLocation
Medifactia DA
  • Healthcare Professionals
    • Overview
      • Validated Method
      • Origin & Development
    • Guidelines & Standards
    • Radiopaque Markers
      • Ingredients
    • Clinical Guidance
      • Reading the results
      • Application
    • Clinical Evidence
  • Patients & Caregivers
    • Colon Transit Study
      • Gastrointestinal Disorders
    • Colon Transit Markers
    • Instructions
  • CTT ReportingSystem
  • Pediatrics
  • CTT Login
  • Order now
  • Menu Menu

Sundhedspersonale

Vi er stolte af at tilbyde state-of-the-art Transit-Pellets røntgen markører, der er designet til at forbedre vurderingen og behandlingen af motilitetsforstyrrelser som forstoppelse, diarré og irritabel tyk tarm (IBS). Vores markører er fremstillet i henhold til Transit-Pellets method. Derudover leverer vi en online standardiseret kolontransit-testrapport, der er designet til behandlende læger og radiologer.

Learn more
International experts (Mayo, Gothenburg and others) states that there are two transit methods able to differ between subtypes of functional disorders of the lower gastrointestinal tract and healthy individuals, the Mayo and the Transit-Pellets principle, the latter a study on 359 patients. The authors emphasize that both methods are validated and with respect to radiopaque markers a method with marker ingestion over six days should be preferred.
Keller et al., 2020
Slight differences in performing the test exist between laboratories, with one validated method being the ingestion of 10 radiopaque markers per day for six consecutive days, followed by fluoroscopy imaging on the morning of day 7 to count the remaining markers.
Aziz et al., 2020
The CTT of normal healthy children is not sex- or age-related (above the age of 3 years). The Abrahamson method for CTT measurement by using bony landmarks for the determination of colon segments is easy to perform and well tolerated with a virtual inexistent rating difference between different observers
Velde et al., 2013
Investigations of anorectal manometry, endosonography and colonic transit studies provide noninvasive objective assessment of diagnosis and severity of chronic IC and fecal incontinence in children. This information is valuable for the clinician to plan the treatment strategy and for parents and children to understand the underlying pathophysiology.
Keshtgar et al., 2013
CTT provides an objective measure to assess childhood constipation. To date, 6 studies using 5 different methods have been published reporting values for healthy children. Comparing these, Abrahamson’s method has low radiation exposure and is well tolerated. This study contributes additional normal values in children.
Wagener et al., 2004
ForrigeNæste

International experts (Mayo, Gothenburg and others) states that there are two transit methods able to differ between subtypes of functional disorders of the lower gastrointestinal tract and healthy individuals, the Mayo and the Transit-Pellets principle, the latter a study on 359 patients. The authors emphasize that both methods are validated and with respect to radiopaque markers a method with marker ingestion over six days should be preferred.

Keller et al., 2020

Slight differences in performing the test exist between laboratories, with one validated method being the ingestion of 10 radiopaque markers per day for six consecutive days, followed by fluoroscopy imaging on the morning of day 7 to count the remaining markers.

Aziz et al., 2020

The CTT of normal healthy children is not sex- or age-related (above the age of 3 years). The Abrahamson method for CTT measurement by using bony landmarks for the determination of colon segments is easy to perform and well tolerated with a virtual inexistent rating difference between different observers

Velde et al., 2013

Investigations of anorectal manometry, endosonography and colonic transit studies provide noninvasive objective assessment of diagnosis and severity of chronic IC and fecal incontinence in children. This information is valuable for the clinician to plan the treatment strategy and for parents and children to understand the underlying pathophysiology.

Keshtgar et al., 2013

CTT provides an objective measure to assess childhood constipation. To date, 6 studies using 5 different methods have been published reporting values for healthy children. Comparing these, Abrahamson’s method has low radiation exposure and is well tolerated. This study contributes additional normal values in children.

Wagener et al., 2004
ForrigeNæste

En tyktarmsundersøgelse med Transit-Pellets anvendes hyppigt hos patienter, der lider af kronisk forstoppelse, kronisk diarré og/eller irritabel tyk tarm (IBS). Formålet med denne test er at vurdere transittiden, og hvor hurtigt eller langsomt maden/fæces bevæger sig gennem tarmene. Testen involverer oral indtagning af syv kapsler over en periode på seks dage, der hver indeholder små markører, som kan visualiseres med røntgen. Indtagningen af markørerne er sikkert, og markørerne vil blive fjernet i fæces og kan bortskaffes sikkert ved at skylle dem ud i toilettet.

  • FDA 510(k) afstand til brug ved voksne patienter
  • FDA 510(k) afstand til brug ved pædiatriske patienter (≥2 år)
  • CE-mærket (til brug ved voksne patienter)
  • Indkapslede tyktarmstransitmarkører
  • Komplet vegetariske kapsler
  • Nemt at administrere
  • Fremstillet i Sverige
Learn more

Valideret metode og sikre colon transit røntgen markører til kvantitativ vurdering af den samlede og regionale tyktarmstransit

Transit-Pellets method og Transit-Pellets radio-uigennemsigtige markører (radiopaque markers) kan anvendes til følgende:

  • at måle hurtig, normal og langsom tyktarmstransit
  • at skelne mellem langsom transit og normal transitforstoppelse
  • at identificere segmentopdelt tyktarmsdysfunktion hos patienter med forstoppelse
  • at skelne mellem normal og hurtig transitdiarré
  • at identificere behandlingseffekter hos patienter med kronisk forstoppelse

En tyktarmstransittest med Transit-Pellets method, tidligere kendt som Abrahamssons method, og Transit-Pellets røntgen markører kan kvantificere transitproblemernes alvorlighed. Testen kan være vigtig for at bestemme behovet for yderligere undersøgelsesprocedurer, vælge den passende behandling og fastsætte en langfristet prognose. Testresultaterne kan anvendes som hjælp til beslutningstagning på disse områder.

Der kan findes henvisninger i afsnittet VALIDATED METHOD.

Illustration af Transit-Pellets-markørbevægelse

Få nøjagtige resultater med Transit-Pellets CTT Reporting System:
Den standardiserede online tyktarmstransit-testrapport for læger og radiologer

Hos Medifactia forstår vi vigtigheden af nøjagtige og pålidelige testresultater inden for det medicinske område. Derfor har vi oprettet en standardiseret online tyktarmstransit-testrapport specifikt til behandlende læger og radiologer. Med denne rapport får du adgang til præcise og komplette tyktarmstransitprofiler for hver patient, hvilket kan give retning for yderligere undersøgelser eller behandlingsstrategier.

Med patientens røntgenbillede i hånden kan du tælle de resterende markører og indtaste antallet som anvist i CTT Reporting System. Systemet opretter derefter en sammenfattende rapport, der inkluderer:

  • en illustration af tyktarmen med det pågældende antal markører i hvert af de fire tyktarmssegmenter
  • en tabel, der viser oplysninger om patientens samlede transittid for tyktarmen sammenlignet med fastlagte referenceværdier
  • en grafisk visning af patientens samlede transittid for tyktarmen sammenlignet med fastlagte referenceværdier
  • Vejledning om, hvordan patientens resultater skal anvendes til at fastlægge den individuelle behandlingsplan eller rådgive om yderligere typer af tests

Denne innovative transittestrapport, der oprettes af CTT Reporting System, er beregnet til at inddrage og informere patienter med henblik på at fremlægge komplekse oplysninger på en måde, der er let forståelig og interessant.

Learn more
See how
Login

Questions?

Contact Us. We’re here to help!

Diana Nyström
+46 (0) 8-460 072 06
diana.nystrom@medifactia.com

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

Medifactia AB

Postal Address:
Lumaparksvägen 7
SE 120 31 Stockholm

Visiting Address:
Ljusslingan 4, floor 8
SE 120 31 Stockholm

Phone: +46 (0) 8-460 072 06
E-mail: info@medifactia.com

Business hours Monday to Friday from 8:00am to 5:00pm

Read more

About Medifactia AB
Terms of Use
Privacy Statement

Tools

CTT Reporting System
Downloads

Distributors

Medifactia Toolbox
The information on this website is for your general information only. Information you read on this website cannot replace the relationship that you have with your health care professional and is not intended to affect that relationship in any way. Medifactia does not practice medicine or provide medical services or advice, and the information on this website should not be considered medical advice. You should always talk to your health care professional for diagnosis and treatment. Health information changes quickly. Therefore, it is always best to confirm information with your health care professional.

Powered by Panzify
Scroll to top

Clinical Decision Support Tool – Irritable Bowel Syndrome1


1. https://svenskgastroenterologi.se. The Clinical Decision Algorithm has undergone minor adjustments compared to the original version.

Patienter & Pårørende

Hver Patient er Unik.
Forstå Dine Gastrointestinale MOTILITETS problemer.

Læs mere